Rapid and Extensive Expansion in the United States of a New Multidrug-resistantEscherichia coliClonal Group, Sequence Type 1193 | Zendy

Veronika Tchesnokova | Zendy; Elena Rechkina | Zendy; Lydia Larson | Zendy; Kendra Ferrier | Zendy; Jamie Lee Weaver | Zendy; David W. Schroeder | Zendy; Rosemary C. She | Zendy; Susan M. ButlerWu | Zendy; Maria E. AgueroRosenfeld | Zendy; Danielle M. Zerr | Zendy; Ferric C. Fang | Zendy; James D. Ralston | Zendy; Kim Riddell | Zendy; Delia Scholes | Zendy; Scott J. Weissman | Zendy; Kaveri S. Parker | Zendy; Brad Spellberg | Zendy; James R. Johnson | Zendy; Evgeni V. Sokurenko | Zendy

Open Access

Rapid and Extensive Expansion in the United States of a New Multidrug-resistantEscherichia coliClonal Group, Sequence Type 1193

Author(s) -

Veronika Tchesnokova,

Elena Rechkina,

Lydia Larson,

Kendra Ferrier,

Jamie Lee Weaver,

David W. Schroeder,

Rosemary C. She,

Susan M. ButlerWu,

Maria E. AgueroRosenfeld,

Danielle M. Zerr,

Ferric C. Fang,

James D. Ralston,

Kim Riddell,

Delia Scholes,

Scott J. Weissman,

Kaveri S. Parker,

Brad Spellberg,

James R. Johnson,

Evgeni V. Sokurenko

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy525

Subject(s) - tetracycline , escherichia coli , sulfamethoxazole , trimethoprim , multiple drug resistance , clone (java method) , microbiology and biotechnology , sequence (biology) , medicine , multilocus sequence typing , biology , antibiotics , genotype , genetics , dna , gene

We describe the rapid and ongoing emergence across multiple US cities of a new multidrug-resistant Escherichia coli clone-sequence type (ST) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (53%). ST1193 is associated with younger adults (age <40 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research